LRRK2 Inhibits FAK Activity by Promoting FERM-mediated Autoinhibition of FAK and Recruiting the Tyrosine Phosphatase, SHP-2.
- Author:
Insup CHOI
1
;
Ji won BYUN
;
Sang Myun PARK
;
Ilo JOU
;
Eun Hye JOE
Author Information
- Publication Type:Original Article
- Keywords: Parkinson's disease; LRRK2; FAK; phosphatase; SHP-2
- MeSH: Focal Adhesion Protein-Tyrosine Kinases; Glutamic Acid; Parkinson Disease; Phosphoric Monoester Hydrolases; Phosphorylation; Phosphotransferases; Protein Tyrosine Phosphatase, Non-Receptor Type 11*; Threonine; Tyrosine*
- From:Experimental Neurobiology 2016;25(5):269-276
- CountryRepublic of Korea
- Language:English
- Abstract: Mutation of leucine-rich repeat kinase 2 (LRRK2) causes an autosomal dominant and late-onset familial Parkinson's disease (PD). Recently, we reported that LRRK2 directly binds to and phosphorylates the threonine 474 (T474)-containing Thr-X-Arg(Lys) (TXR) motif of focal adhesion kinase (FAK), thereby inhibiting the phosphorylation of FAK at tyrosine (Y) 397 residue (pY397-FAK), which is a marker of its activation. Mechanistically, however, it remained unclear how T474-FAK phosphorylation suppressed FAK activation. Here, we report that T474-FAK phosphorylation could inhibit FAK activation via at least two different mechanisms. First, T474 phosphorylation appears to induce a conformational change of FAK, enabling its N-terminal FERM domain to autoinhibit Y397 phosphorylation. This is supported by the observation that the levels of pY397-FAK were increased by deletion of the FERM domain and/or mutation of the FERM domain to prevent its interaction with the kinase domain of FAK. Second, pT474-FAK appears to recruit SHP-2, which is a phosphatase responsible for dephosphorylating pY397-FAK. We found that mutation of T474 into glutamate (T474E-FAK) to mimic phosphorylation induced more strong interaction with SHP-2 than WT-FAK, and that pharmacological inhibition of SHP-2 with NSC-87877 rescued the level of pY397 in HEK293T cells. These results collectively show that LRRK2 suppresses FAK activation through diverse mechanisms that include the promotion of autoinhibition and/or the recruitment of phosphatases, such as SHP-2.
